Inhibition of glucagon secretion by GLP-1 agonists and DPP4 inhibitors
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Inhibition of glucagon secretion by GLP-1 agonists and DPP4 inhibitors. / Hansen, Morten; Juul Hare, Kristine; Holst, Jens Juul; Knop, Filip Krag.
In: Journal of Clinical Metabolism & Diabetes, Vol. 2, No. 2, 06.2011, p. 7-13.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Inhibition of glucagon secretion by GLP-1 agonists and DPP4 inhibitors
AU - Hansen, Morten
AU - Juul Hare, Kristine
AU - Holst, Jens Juul
AU - Knop, Filip Krag
PY - 2011/6
Y1 - 2011/6
N2 - Incretin-based treatments have emerged as new modalities for the treatment of type 2 diabetes mellitus (T2DM). In contrast to currentantidiabetic treatments, these agents target both insulin insufficiency and inappropriate hyperglucagonemia*two major components of type2 diabetic pathophysiology*both known to contribute significantly to the hyperglycemic state of patients with T2DM. This article outlines therole of hyperglucagonemia in type 2 diabetic pathophysiology, summarizes the physiologic effects of glucagon-like peptide-1 (GLP-1), andgives an introduction to incretin-based treatments with emphasis on their glucagon-lowering effects. Finally, we review available glucagondata from current clinical studies on incretin-based treatment modalities (dipeptidyl peptidase 4 [DPP4] inhibitors and GLP-1 receptoragonists). Most of these studies suggest that both DPP4 inhibitors and GLP-1 receptor agonists lower fasting and postprandial plasmaglucagon, and recent data suggest that these effects contribute importantly to the glucose-lowering effect of these treatments.
AB - Incretin-based treatments have emerged as new modalities for the treatment of type 2 diabetes mellitus (T2DM). In contrast to currentantidiabetic treatments, these agents target both insulin insufficiency and inappropriate hyperglucagonemia*two major components of type2 diabetic pathophysiology*both known to contribute significantly to the hyperglycemic state of patients with T2DM. This article outlines therole of hyperglucagonemia in type 2 diabetic pathophysiology, summarizes the physiologic effects of glucagon-like peptide-1 (GLP-1), andgives an introduction to incretin-based treatments with emphasis on their glucagon-lowering effects. Finally, we review available glucagondata from current clinical studies on incretin-based treatment modalities (dipeptidyl peptidase 4 [DPP4] inhibitors and GLP-1 receptoragonists). Most of these studies suggest that both DPP4 inhibitors and GLP-1 receptor agonists lower fasting and postprandial plasmaglucagon, and recent data suggest that these effects contribute importantly to the glucose-lowering effect of these treatments.
M3 - Journal article
VL - 2
SP - 7
EP - 13
JO - Journal of Clinical Metabolism & Diabetes
JF - Journal of Clinical Metabolism & Diabetes
SN - 2041-8019
IS - 2
ER -
ID: 38433556